ldtЛучевая диагностика и терапияDiagnostic radiology and radiotherapy2079-5343Baltic Medical Education Center10.22328/2079-5343-2019-10-3-5-13ldt-427Research ArticleРЕДАКЦИОННАЯ СТАТЬЯEDITORIALОСНОВЫ СИСТЕМЫ VI-RADS - КОНЦЕПЦИЯ МУЛЬТИПАРАМЕТРИЧЕСКОЙ МАГНИТНО-РЕЗОНАНСНОЙ ТОМОГРАФИИ ПРИ РАКЕ МОЧЕВОГО ПУЗЫРЯTHE BASICS OF VI-RADS CONCEPT OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF BLADDER CANCERМищенкоА. В.MishchenkoA. V.

Мищенко Андрей Владимирович — доктор медицинских наук, заведующий научным отделением диагностической и интервенционной радиологии

197758, Санкт-Петербург, п. Песочный, Ленинградская ул., д. 68

dr.mishchenko@mail.ruВасильевА. В.VasilievA. V.

Васильев Александр Викторович — врач-рентгенолог, врач ультразвуковой диагностики отделения лучевой диагностики

197758, Санкт-Петербург, п. Песочный, Ленинградская ул., д. 68

alexandr-sgma@yandex.ruПетроваА. С.PetrovaA. S.

Петрова Анна Сергеевна — врач-рентгенолог отделения лучевой диагностики

197758, Санкт-Петербург, п. Песочный, Ленинградская ул., д. 68

a.petrova.05@gmail.comДаниловВ. В.DanilovV. V.

Данилов Всеволод Вячеславович — клинический ординатор отделения лучевой диагностики

197758, Санкт-Петербург, п. Песочный, Ленинградская ул., д. 68

sevadani50@gmail.comНациональный медицинский исследовательский центр онкологии им. Н. Н. ПетроваРоссияNational medical research center of Oncology named after N. N. PetrovRussian Federation20191610201903513Copyright © Мищенко А.В., Васильев А.В., Петрова А.С., Данилов В.В., 20192019Мищенко А.В., Васильев А.В., Петрова А.С., Данилов В.В.Mishchenko A.V., Vasiliev A.V., Petrova A.S., Danilov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://radiag.bmoc-spb.ru/jour/article/view/427

Высокую актуальность рака мочевого пузыря определяют не только высокие цифры заболеваемости, но и широкий спектр лечебных мероприятий, которые зависят от точного определения степени инвазии и распространенности опухолевого заболевания. Хотя решающую роль играют трансуретральная резекция и последующее патоморфологическое исследование, возможность предварительной оценки, а также контроля проводимого лечения при помощи МРТ открывают широкие перспективы. В связи с этим были разработаны критерии использования МРТ при характеристики опухолевого процесса мочевого пузыря. Правила проведения сканирования, а также интерпретации полученных изображений сведены в рекомендации VI-RADS, которые одобрены авторитетными сообществами лучевых диагностов и урологов. Использование этих рекомендаций позволит избежать множества ошибок и повысить взаимопонимание не только среди лучевых диагностов, но и среди лучевых диагностов и урологов.

High relevance of bladder cancer is determined not only by high morbidity rates, but a wide range of therapeutic measures that depend on the exact definition of the degree of invasion and the prevalence of tumor disease. Although transurethral resection and subsequent pathological study plays crucial role opportunity of preliminary assessment and treatment monitoring by using MRI open up broad prospects. In this regard, were developed the criteria of MRI in the access of the bladder tumor. Rules of carrying out scanning, and interpretation of the images are consolidated in recommendation VI-RADS. It has been approved by authoritative societiesof radiologists and urologists. The use of these recommendations will avoid many mistakes and increase understanding among radiologists as well as urologists.

рак мочевого пузырялучевая диагностикаVI-RADSurine bladder cancerdiagnostic imagingVI-RADSReferencesSvatek R.S., Hollenbeck B.K., Holmang S. et al. The economics of bladder cancer: costs and considerations of caring for this disease // Eur. Urol. 2014. Vol. 66. Р. 253–262. DOI: 10.1016/j.eururo.2014.01.006.Svatek R.S., Hollenbeck B.K., Holmang S. et al. The economics of bladder cancer: costs and considerations of caring for this disease // Eur. Urol. 2014. Vol. 66. Р. 253–262. DOI: 10.1016/j.eururo.2014.01.006.Barentsz J.O., Ruijs S.H., Strijk S.P. The role of MR imaging in carcinoma of the urinary bladder // AJR Am. J. Roentgenol. 1993. Vol. 160. Р. 937–947. DOI: 10.2214/ajr.160.5.8470608.Barentsz J.O., Ruijs S.H., Strijk S.P. The role of MR imaging in carcinoma of the urinary bladder // AJR Am. J. Roentgenol. 1993. Vol. 160. Р. 937–947. DOI: 10.2214/ajr.160.5.8470608.Woo S., Suh C.H., Kim S.Y., Cho J.Y., Kim S.H. Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: a systematic review and meta-analysis // Eur. J. Radiol. 2017. Vol. 95. Р. 46–55. DOI: 10.1016/j.ejrad.2017.07.021.Woo S., Suh C.H., Kim S.Y., Cho J.Y., Kim S.H. Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: a systematic review and meta-analysis // Eur. J. Radiol. 2017. Vol. 95. Р. 46–55. DOI: 10.1016/j.ejrad.2017.07.021.Huang L., Kong Q., Liu Z., et al. The Diagnostic valueof MR imaging in differentiating T staging of bladder cancer: a meta-analysis // Radiology. 2018. Vol. 286. Р. 502–511. DOI: 10.1148/radiol.2017171028.Huang L., Kong Q., Liu Z., et al. The Diagnostic valueof MR imaging in differentiating T staging of bladder cancer: a meta-analysis // Radiology. 2018. Vol. 286. Р. 502–511. DOI: 10.1148/radiol.2017171028.Witjes J.A., Comperat E., Cowan N.C. et al. EAU guidelines on muscleinvasive and metastatic bladder cancer:summary of the 2013 guidelines // Eur. Urol. 2014. Vol. 65. Р. 778–792. DOI: 10.1016/j.eururo.2013.Witjes J.A., Comperat E., Cowan N.C. et al. EAU guidelines on muscleinvasive and metastatic bladder cancer:summary of the 2013 guidelines // Eur. Urol. 2014. Vol. 65. Р. 778–792. DOI: 10.1016/j.eururo.2013.Fonteyne V., Ost P., Bellmunt J. et al. Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review // Eur. Urol. 2018. Vol. 73. Р. 40–50. DOI: 10.1016/j.eururo.2017.03.019.Fonteyne V., Ost P., Bellmunt J. et al. Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review // Eur. Urol. 2018. Vol. 73. Р. 40–50. DOI: 10.1016/j.eururo.2017.03.019.Ma W., Kang S.K., Hricak H., Gerst S.R., Zhang J. Imaging appearance of granulomatous disease after intravesical Bacille Calmette- Guerin (BCG) treatment of bladder carcinoma // AJR Am. J. Roentgenol. 2009. Vol. 192. Р. 1494–1500. DOI: 10.2214/AJR.08.1962.Ma W., Kang S.K., Hricak H., Gerst S.R., Zhang J. Imaging appearance of granulomatous disease after intravesical Bacille Calmette- Guerin (BCG) treatment of bladder carcinoma // AJR Am. J. Roentgenol. 2009. Vol. 192. Р. 1494–1500. DOI: 10.2214/AJR.08.1962.Kim B., Semelka R.C., Ascher S.M., Chalpin D.B., Carroll P.R., Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT., T1- and T2-weighted MR imaging, dynamic gadoliniumenhanced imaging, and late gadolinium-enhanced imaging // Radiology. 1994. Vol. 193. Р. 239–245. DOI: 10.1148/radiology.193.1.8090898.Kim B., Semelka R.C., Ascher S.M., Chalpin D.B., Carroll P.R., Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT., T1- and T2-weighted MR imaging, dynamic gadoliniumenhanced imaging, and late gadolinium-enhanced imaging // Radiology. 1994. Vol. 193. Р. 239–245. DOI: 10.1148/radiology.193.1.8090898.Johnson W., Taylor M.B, Carrington B.M., Bonington S.C., Swindell R. The value of hyoscine butylbromide in pelvic MRI // Clin. Radiol. 2007. Vol. 62. Р. 1087–1093. DOI: 10.1016/j.crad.2007.05.007.Johnson W., Taylor M.B, Carrington B.M., Bonington S.C., Swindell R. The value of hyoscine butylbromide in pelvic MRI // Clin. Radiol. 2007. Vol. 62. Р. 1087–1093. DOI: 10.1016/j.crad.2007.05.007.Panebianco V., Barchetti F., de Haas R.J. et al. Improving staging in bladder cancer: the increasing role of multiparametric magnetic resonance imaging // Eur. Urol. Focus. 2016. Vol. 2. Р. 113–121. DOI: 10.1016/j.euf.2016.04.010.Panebianco V., Barchetti F., de Haas R.J. et al. Improving staging in bladder cancer: the increasing role of multiparametric magnetic resonance imaging // Eur. Urol. Focus. 2016. Vol. 2. Р. 113–121. DOI: 10.1016/j.euf.2016.04.010.Takeuchi M., Sasaki S., Ito M. et al. Urinary bladder cancer: diffusionweighted MR imaging accuracy for diagnosing T stage and estimating histologic grade // Radiology. 2009. Vol. 251. Р. 112–121. DOI: 10.1148/radiol.2511080873.Takeuchi M., Sasaki S., Ito M. et al. Urinary bladder cancer: diffusionweighted MR imaging accuracy for diagnosing T stage and estimating histologic grade // Radiology. 2009. Vol. 251. Р. 112–121. DOI: 10.1148/radiol.2511080873.Donaldson S.B., Bonington S.C., Kershaw L.E. et al. Dynamic contrastenhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect // Eur. J. Radiol. 2013. Vol. 82. Р. 2161–2168. DOI: 10.1016/j.ejrad.2013.08.008.Donaldson S.B., Bonington S.C., Kershaw L.E. et al. Dynamic contrastenhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect // Eur. J. Radiol. 2013. Vol. 82. Р. 2161–2168. DOI: 10.1016/j.ejrad.2013.08.008.Zhou G., Chen X., Zhang J., Zhu J., Zong G., Wang Z. Contrastenhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer // Eur. J. Radiol. 2014. Vol. 83. Р. 2013–2018. DOI: 10.1016/j.ejrad.2014.08.012.Zhou G., Chen X., Zhang J., Zhu J., Zong G., Wang Z. Contrastenhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer // Eur. J. Radiol. 2014. Vol. 83. Р. 2013–2018. DOI: 10.1016/j.ejrad.2014.08.012.Narumi Y., Kadota T., Inoue E. et al. Bladder wall morphology: in vitro MR imaging-histopathologic correlation // Radiology. 1993. Vol. 187. Р. 151–155. DOI: 10.1148/radiology.187.1.8451403.Narumi Y., Kadota T., Inoue E. et al. Bladder wall morphology: in vitro MR imaging-histopathologic correlation // Radiology. 1993. Vol. 187. Р. 151–155. DOI: 10.1148/radiology.187.1.8451403.Narumi Y., Kadota T., Inoue E. et al. Bladder tumors: staging with gadolinium-enhanced oblique MR imaging // Radiology. 1993. Vol. 187. Р. 145–150. DOI: 10.1148/radiology.187.1.8451401.Narumi Y., Kadota T., Inoue E. et al. Bladder tumors: staging with gadolinium-enhanced oblique MR imaging // Radiology. 1993. Vol. 187. Р. 145–150. DOI: 10.1148/radiology.187.1.8451401.Cheong J.J.W., Woodward P.J., Maria A., Davis C.J. From the archives of the AFIP inflammatory and nonneoplastic bladder masses: radiologic-pathologic objectives // RadioGraphics. 2006. Vol. 1595. Р. 1847–1869. DOI: 10.1148/rg.266065126.Cheong J.J.W., Woodward P.J., Maria A., Davis C.J. From the archives of the AFIP inflammatory and nonneoplastic bladder masses: radiologic-pathologic objectives // RadioGraphics. 2006. Vol. 1595. Р. 1847–1869. DOI: 10.1148/rg.266065126.El-Assmy A., Abou-El-Ghar M.Е., Refaie H.F., Mosbah A., El- Diasty T. Diffusion-weighted magnetic resonance imaging in followup of superficial urinary bladder carcinoma after transurethral resection: initial experience // BJU Int. 2012. Vol. 110E. Р. 622–627. DOI: 10.1111/j.1464–410X.2012.11345.x.El-Assmy A., Abou-El-Ghar M.Е., Refaie H.F., Mosbah A., El- Diasty T. Diffusion-weighted magnetic resonance imaging in followup of superficial urinary bladder carcinoma after transurethral resection: initial experience // BJU Int. 2012. Vol. 110E. Р. 622–627. DOI: 10.1111/j.1464–410X.2012.11345.x.Wang H.J., Pui M.H., Guo Y., Yang D., Pan B.T., Zhou X.H. Diffusionweighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection // Abdom. Imaging. 2014. Vol. 39. Р. 135–141.Wang H.J., Pui M.H., Guo Y., Yang D., Pan B.T., Zhou X.H. Diffusionweighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection // Abdom. Imaging. 2014. Vol. 39. Р. 135–141.Seiji N., Shojiro M., Yasuyuki Y. General Rule for Clinical and Pathological Studies on Renal Pelvic, Ureteral and Bladder Cancer. 1st edn. Tokyo, Kanehara-publisher, 2011.Seiji N., Shojiro M., Yasuyuki Y. General Rule for Clinical and Pathological Studies on Renal Pelvic, Ureteral and Bladder Cancer. 1st edn. Tokyo, Kanehara-publisher, 2011.Wang F., Wu L.M., Hua X.L., Zhao Z.Z., Chen X.X., Xu J.R. Intravoxel incoherent motion diffusion-weighted imaging in assessing bladder cancer invasiveness and cell proliferation // J. Magn. Reson. Imaging. 2018. Vol. 47. Р. 1054–1060. DOI: 10.1002/jmri.25839.Wang F., Wu L.M., Hua X.L., Zhao Z.Z., Chen X.X., Xu J.R. Intravoxel incoherent motion diffusion-weighted imaging in assessing bladder cancer invasiveness and cell proliferation // J. Magn. Reson. Imaging. 2018. Vol. 47. Р. 1054–1060. DOI: 10.1002/jmri.25839.International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-urinary Tract Cancer Group. et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial // J. Clin. Oncol. 2011. Vol. 29. Р. 2171–2177. DOI: 10.1200/JCO.2010.32.3139.International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-urinary Tract Cancer Group. et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial // J. Clin. Oncol. 2011. Vol. 29. Р. 2171–2177. DOI: 10.1200/JCO.2010.32.3139.Seisen T., Sun M., Lipsitz S.R. et al. Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscleinvasive urothelial carcinoma of the bladder // Eur. Urol. 2017. Vol. 72. Р. 483–487. DOI: 10.1016/j.eururo.2017.03.038.Seisen T., Sun M., Lipsitz S.R. et al. Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscleinvasive urothelial carcinoma of the bladder // Eur. Urol. 2017. Vol. 72. Р. 483–487. DOI: 10.1016/j.eururo.2017.03.038.Nguyen H.T., Jia G., Shah Z.K. et al. Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrastenhanced (DCE)-MRI pharmacokinetic parameters // J. Magn. Reson. Imaging. 2015. Vol. 41. Р. 1374–1382. DOI: 10.1002/jmri.24663.Nguyen H.T., Jia G., Shah Z.K. et al. Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrastenhanced (DCE)-MRI pharmacokinetic parameters // J. Magn. Reson. Imaging. 2015. Vol. 41. Р. 1374–1382. DOI: 10.1002/jmri.24663.Yoshida S., Koga F., Kawakami S., et al. Initial experience of diffusionweighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer // Urology. 2010. Vol.75. Р. 387–391. DOI: 10.1016/j.urology.2009.06.111.Yoshida S., Koga F., Kawakami S., et al. Initial experience of diffusionweighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer // Urology. 2010. Vol.75. Р. 387–391. DOI: 10.1016/j.urology.2009.06.111.Johnson R.J., Carrington B.M., Jenkins J.P., Barnard R.J., Read G., Isherwood I. Accuracy in staging carcinoma of the bladder by magnetic resonance imaging // Clin. Radiol. 1990. Vol. 41. Р. 258–263. DOI: 10.1016/S0009–9260(05)81661–7.Johnson R.J., Carrington B.M., Jenkins J.P., Barnard R.J., Read G., Isherwood I. Accuracy in staging carcinoma of the bladder by magnetic resonance imaging // Clin. Radiol. 1990. Vol. 41. Р. 258–263. DOI: 10.1016/S0009–9260(05)81661–7.Barentsz J.O., Jager G.J., van Vierzen P.B. et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrastenhanced MR imaging // Radiology. 1996. Vol. 201. Р. 185–193. DOI: 10.1148/radiology.201.1.8816542.Barentsz J.O., Jager G.J., van Vierzen P.B. et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrastenhanced MR imaging // Radiology. 1996. Vol. 201. Р. 185–193. DOI: 10.1148/radiology.201.1.8816542.Mak R.H., Hunt D., Shipley W.U. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladderpreserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233 // J. Clin. Oncol. 2014. Vol. 32. Р. 3801–3809. DOI: 10.1200/JCO.2014.57.5548.Mak R.H., Hunt D., Shipley W.U. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladderpreserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233 // J. Clin. Oncol. 2014. Vol. 32. Р. 3801–3809. DOI: 10.1200/JCO.2014.57.5548.Yoshida S., Koga F., Kobayashi S. et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer // Int. J. Radiat. Oncol. Biol. Phys. 2012. Vol. 83. Р. 21–27. DOI: 10.1016/j.ijrobp.2011.11.065Yoshida S., Koga F., Kobayashi S. et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer // Int. J. Radiat. Oncol. Biol. Phys. 2012. Vol. 83. Р. 21–27. DOI: 10.1016/j.ijrobp.2011.11.065Schrier B.P., Peters M., Barentsz J.O., Witjes J.A. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer // Eur. Urol. 2006. Vol. 49. Р. 698–703. DOI: 10.1016/j.eururo.2006.01.022Schrier B.P., Peters M., Barentsz J.O., Witjes J.A. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer // Eur. Urol. 2006. Vol. 49. Р. 698–703. DOI: 10.1016/j.eururo.2006.01.022O’Connor J.P., Aboagye E.O., Adams J.E. et al. Imaging biomarker roadmap for cancer studies // Nat. Rev. Clin. Oncol. 2017. Vol. 14. Р. 169–86. DOI: 10.1038/nrclinonc.2016.162.O’Connor J.P., Aboagye E.O., Adams J.E. et al. Imaging biomarker roadmap for cancer studies // Nat. Rev. Clin. Oncol. 2017. Vol. 14. Р. 169–86. DOI: 10.1038/nrclinonc.2016.162.

The authors declare that there are no conflicts of interest present.